AbCellera Biologics Inc. is a clinical-stage biotechnology company that discovers and develops antibody-based medicines. Based in Vancouver, Canada, the company utilizes an artificial intelligence-powered drug discovery platform to analyze immune systems and identify therapeutic antibodies. AbCellera partners with pharmaceutical companies to co-develop drugs while also advancing its own internal pipeline of proprietary clinical candidates.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
75,128
28,833
38,025
485,424
Gross Profit
75,128
28,833
38,025
485,424
Selling, General & Administrative Expenses
83,231
85,490
75,179
66,755
Depreciation & Amortization Expenses
22,171
90,850
24,395
27,843
Research & Development Expenses
186,829
167,259
175,658
107,879
Other Operating Expenses
—
—
—
66,436
Operating Profit
(217,103)
(314,766)
(237,207)
216,511
Interest and Investment Income
28,329
38,473
42,247
16,079
Non-Operating Income
11,179
75,898
20,931
6,509
Total Non-Operating Income
39,508
114,371
63,178
22,588
Income Before Provision for Income Taxes
(177,595)
(200,395)
(174,029)
239,099
Provision for Income Taxes
(31,183)
(37,538)
(27,631)
80,580
Consolidated Net Income
(146,412)
(162,857)
(146,398)
158,519
Net Income Attributable to Common Shareholders
(146,412)
(162,857)
(146,398)
158,519
Basic EPS
-0.49
-0.55
-0.51
0.56
Diluted EPS
-0.49
-0.55
-0.51
0.50
Basic Weighted Average Shares Outstanding
298,707
294,328
289,166
285,057
Diluted Weighted Average Shares Outstanding
298,707
294,328
289,166
314,827
Shares Outstanding
300,601
295,757
290,825
286,852
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
128,513
156,325
133,320
386,535
Short-Term Investments
405,313
469,289
627,265
499,950
Total Cash and Cash Equivalents
533,826
625,614
760,585
886,485
Accounts Receivable
58,293
33,616
30,590
38,593
Total Trade Receivables
58,293
33,616
30,590
38,593
Other Current Assets
136,113
92,140
80,810
100,413
Total Current Assets
728,232
751,370
871,985
1,025,491
Net Property, Plant & Equipment
428,003
340,429
287,696
217,255
Net Intangible Assets
38,381
42,113
120,425
131,502
Goodwill
47,806
47,806
47,806
47,806
Long-Term Investments
62,580
82,297
65,938
72,522
Other Long-Term Assets
51,948
96,538
94,244
46,331
Total Assets
1,356,950
1,360,553
1,488,094
1,540,907
Accounts Payable
50,781
55,004
49,580
52,497
Unearned Revenue
13,526
13,521
18,958
21,612
Other Current Liabilities
—
8,087
50,475
44,211
Total Current Liabilities
64,307
76,612
119,013
118,320
Leases
137,403
60,743
71,222
76,675
Other Long-Term Liabilities
188,336
167,114
145,541
112,635
Total Long-Term Liabilities
325,739
227,857
216,763
189,310
Total Liabilities
390,046
304,469
335,776
307,630
Common Stock
802,341
777,171
753,199
734,365
Additional Paid-in Capital
198,279
166,361
121,052
74,118
Accumulated Other Comprehensive Income
(4,234)
(4,378)
(1,720)
(1,391)
Retained Earnings
(29,482)
116,930
279,787
426,185
Total Common Shareholders' Equity
966,904
1,056,084
1,152,318
1,233,277
Total Shareholders' Equity
966,904
1,056,084
1,152,318
1,233,277
Total Liabilities and Shareholders' Equity
1,356,950
1,360,553
1,488,094
1,540,907
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
(146,412)
(162,857)
(146,398)
158,519
Depreciation & Amortization
28,821
96,998
30,894
33,102
Share-Based Compensation Expense
55,792
67,581
64,183
49,481
Other Adjustments
1,198
(84,435)
(5,781)
6,433
Changes in Trade Receivables
(55,623)
(75,119)
(45,933)
106,456
Changes in Accounts Payable
3,457
10,635
(15,104)
(2,094)
Changes in Income Taxes Payable
(29,843)
6,651
30,464
(88,609)
Changes in Unearned Revenue
(5,833)
26,036
25,545
15,447
Changes in Other Operating Activities
17,148
5,954
18,253
(1,375)
Cash from Operating Activities
(131,295)
(108,556)
(43,877)
277,360
Capital Expenditure
(42,772)
(78,396)
(76,947)
(70,660)
Purchases of Intangible Assets
—
—
—
(2,000)
Purchases of Investments
(443,181)
(784,712)
(1,035,200)
(789,661)
Proceeds from Sale of Investments
506,072
937,882
910,937
510,631
Other Investing Activities
67,631
46,635
(19,898)
(935)
Cash from Investing Activities
87,750
121,409
(221,108)
(352,625)
Other Financing Activities
14,082
12,769
10,356
(1,628)
Cash from Financing Activities
14,082
12,769
10,356
(1,628)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
1,097
(2,617)
589
(9,599)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash